Industry & Policy News

[Fred Hutchinson Cancer Center] Dr. Hans-Peter Kiem was awarded $480,000 by amfAR, The Foundation for AIDS Research, to support the next stage of his work. Dr. Kiem is pursuing an in vivo gene therapy that confers HIV resistance to a specific subset of a patient’s hematopoietic stem cells.

[ImPact Biotech (Globe Newswire)] The planned Phase I/Ib, safety, feasibility, and light dose titration study followed by further study of therapeutic ablation effects, is designed as a multicenter, open-label study of Padeliporfin Vascular Targeted Photodynamic using Robotic Assisted Bronchoscopy and cone beam CT guidance for lung tumor ablation in patients with Peripheral Lung Cancer.

[Lisata Therapeutics, Inc.] The FDA has granted orphan drug designation to LSTA1 for use as a potential therapeutic option in patients with malignant glioma, according to an announcement from Lisata Therapeutics, Inc.

[TOMI Environmental Solutions, Inc.] TOMI Environmental Solutions, Inc.® announced a collaboration with Cellares to integrate its SteraMist ionized Hydrogen Peroxide (iHP) technology into a revolutionary new cell therapy manufacturing solution, the Cell Shuttle, designed and produced by Cellares.

[STAT News] For what would have been Henrietta Lacks’ 103th birthday, her family got her some justice: A settlement with Thermo Fisher Scientific over the Massachusetts-based company’s use of cells obtained without her consent seven decades ago.

[Nature] Under-representation of people of color sparks concerns over the safety and efficacy of drugs in diverse populations. Black and Hispanic people are up to twice as likely as white people to develop Alzheimer’s disease, but they have a much lower chance of being included in clinical trials for Alzheimer’s treatments.